TG Therapeutics
TGTX
115 hedge funds and large institutions have $272M invested in TG Therapeutics in 2019 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 43 increasing their positions, 27 reducing their positions, and 17 closing their positions.
279% more call options, than puts
Call options by funds: $8.3M | Put options by funds: $2.19M
59% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 27
0% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 17
1% less funds holding
Funds holding: 116 → 115 (-1)
4.25% less ownership
Funds ownership: 55.31% → 51.06% (-4.2%)
37% less capital invested
Capital invested by funds: $434M → $272M (-$162M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$15.1M |
| 2 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$3.29M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$2.47M |
| 4 |
BlackRock
New York
|
+$2.12M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$9.2M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$8.65M |
| 3 |
BM
Bridger Management
New York
|
-$7.53M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$5.96M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$4.74M |
TGTX Hedge Fund Activity: Q3 2019 in Review
115 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q3 2019, worth a combined $272M — down 37% from $434M a quarter earlier.
Fund positioning in TGTX was balanced in Q3 2019: 17 funds opened new positions, 17 closed out, 43 added to existing stakes and 27 trimmed.
The largest buyer was Millennium Management, adding an estimated $15.1M. The largest seller was State Street, cutting an estimated $9.2M.
- 115 institutional investors held TG Therapeutics (TGTX) as of Q3 2019, down from 116 in Q2 2019.
- Funds reported $272M of TG Therapeutics stock for Q3 2019, down 37% quarter-over-quarter.
- 17 funds opened new TG Therapeutics positions in Q3 2019 and 17 closed out, a net change of 0 holders.
- The largest TG Therapeutics buyer in Q3 2019 was Millennium Management, an estimated $15.1M added.
- The largest TG Therapeutics seller in Q3 2019 was State Street, an estimated $9.2M sold.
Based on aggregated 13F filings for Q3 2019.